Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe

NCT04579679 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT04579679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04579679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
Lead sponsor
Hutchmed
Phase
Phase 2
Overall status
Terminated
Start date
August 13, 2021
Completion date
October 15, 2024
Enrollment
78 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumour of the lung, neuroendocrine tumours, small intestinal net